Рет қаралды 475
CMT Research Foundation recently hosted a webinar featuring Dr. Jorge A. Quiroz (NMD Pharma), Dr. Carlos Loya (82VS, an Alloy Therapeutics, Inc. Venture Studio) and Peter deSilva (CMTRF Board Chair and ENDGAME Chair). The webinar highlighted two major events that are underway for CMT.
Dr. Quiroz spoke about NMD Pharma receiving approval to initiate a Phase 2 clinical trial of NMD670 in patients living with CMT types 1 and 2.
Dr. Loya spoke about a new technology for CMT drug development and highlighted the delivery vehicle designed to carry genetic therapies to the peripheral nervous system
For more information, visit cmtrf.org/endgame.